JP2021503930A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021503930A5 JP2021503930A5 JP2020529419A JP2020529419A JP2021503930A5 JP 2021503930 A5 JP2021503930 A5 JP 2021503930A5 JP 2020529419 A JP2020529419 A JP 2020529419A JP 2020529419 A JP2020529419 A JP 2020529419A JP 2021503930 A5 JP2021503930 A5 JP 2021503930A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- nucleotide
- seq
- nucleotide sequence
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 139
- 239000002773 nucleotide Substances 0.000 claims 110
- 230000000692 anti-sense effect Effects 0.000 claims 38
- 108020004459 Small interfering RNA Proteins 0.000 claims 35
- 108091081021 Sense strand Proteins 0.000 claims 33
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 6
- 125000002521 alkyl halide group Chemical group 0.000 claims 5
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 5
- 241000700721 Hepatitis B virus Species 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 229910019142 PO4 Inorganic materials 0.000 claims 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 3
- -1 alkyl group halide Chemical class 0.000 claims 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000010452 phosphate Substances 0.000 claims 3
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims 2
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 claims 2
- 125000000732 arylene group Chemical group 0.000 claims 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- KGSURTOFVLAWDC-DGPNFKTASA-N (2R,3R,4R,5R,6R)-6-(hydroxymethyl)-5-sulfanyloxane-2,3,4-triol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1S KGSURTOFVLAWDC-DGPNFKTASA-N 0.000 claims 1
- KNWYARBAEIMVMZ-VFUOTHLCSA-N (2r,3r,4s,5s,6r)-6-(hydroxymethyl)thiane-2,3,4,5-tetrol Chemical compound OC[C@H]1S[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O KNWYARBAEIMVMZ-VFUOTHLCSA-N 0.000 claims 1
- ZXNYUXIMAXVSFN-VFUOTHLCSA-N 2,2,2-trifluoro-n-[(2r,3r,4r,5r,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound OC[C@H]1O[C@@H](O)[C@H](NC(=O)C(F)(F)F)[C@@H](O)[C@H]1O ZXNYUXIMAXVSFN-VFUOTHLCSA-N 0.000 claims 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 1
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 claims 1
- NRDFDUPNSZMPNB-UTSKFRMZSA-N C(C)[C@@]1(S)C[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](S1)[C@H](OC(C)=O)COC(C)=O Chemical compound C(C)[C@@]1(S)C[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](S1)[C@H](OC(C)=O)COC(C)=O NRDFDUPNSZMPNB-UTSKFRMZSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-DHVFOXMCSA-N L-galactose Chemical compound OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-DHVFOXMCSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-ZZWDRFIYSA-N L-glucose Chemical compound OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-ZZWDRFIYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-JFNONXLTSA-N L-mannopyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-JFNONXLTSA-N 0.000 claims 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 1
- FDJKUWYYUZCUJX-VTERZIIISA-N N-glycoloyl-alpha-neuraminic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H]1O[C@@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-VTERZIIISA-N 0.000 claims 1
- PRDZVHCOEWJPOB-IVMDWMLBSA-N N-sulfo-D-glucosamine Chemical compound OC[C@H]1OC(O)[C@H](NS(O)(=O)=O)[C@@H](O)[C@@H]1O PRDZVHCOEWJPOB-IVMDWMLBSA-N 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
- PYMYPHUHKUWMLA-MROZADKFSA-N aldehydo-L-ribose Chemical compound OC[C@H](O)[C@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-MROZADKFSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- RFSUNEUAIZKAJO-ZXXMMSQZSA-N alpha-D-fructofuranose Chemical compound OC[C@H]1O[C@@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ZXXMMSQZSA-N 0.000 claims 1
- LKDRXBCSQODPBY-ZXXMMSQZSA-N alpha-D-fructopyranose Chemical compound OC[C@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-ZXXMMSQZSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- GZCGUPFRVQAUEE-UHFFFAOYSA-N alpha-D-galactose Natural products OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 claims 1
- AVVWPBAENSWJCB-UKFBFLRUSA-N alpha-D-glucofuranose Chemical compound OC[C@@H](O)[C@H]1O[C@H](O)[C@H](O)[C@H]1O AVVWPBAENSWJCB-UKFBFLRUSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 claims 1
- 108010006523 asialoglycoprotein receptor Proteins 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- AVVWPBAENSWJCB-DGPNFKTASA-N beta-D-galactofuranose Chemical compound OC[C@@H](O)[C@@H]1O[C@@H](O)[C@H](O)[C@H]1O AVVWPBAENSWJCB-DGPNFKTASA-N 0.000 claims 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 claims 1
- AVVWPBAENSWJCB-QZABAPFNSA-N beta-D-glucofuranose Chemical compound OC[C@@H](O)[C@H]1O[C@@H](O)[C@H](O)[C@H]1O AVVWPBAENSWJCB-QZABAPFNSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-RWOPYEJCSA-N beta-D-mannose Chemical compound OC[C@H]1O[C@@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-RWOPYEJCSA-N 0.000 claims 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 1
- 229960002246 beta-d-glucopyranose Drugs 0.000 claims 1
- MSFSPUZXLOGKHJ-KTZFPWNASA-N beta-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O MSFSPUZXLOGKHJ-KTZFPWNASA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229960003082 galactose Drugs 0.000 claims 1
- 229960002442 glucosamine Drugs 0.000 claims 1
- 229960001031 glucose Drugs 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000002390 hyperplastic effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023160064A JP7702159B2 (ja) | 2017-12-01 | 2023-09-25 | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711249333.8 | 2017-12-01 | ||
| CN201711249333 | 2017-12-01 | ||
| CN201711482970.X | 2017-12-29 | ||
| CN201711482970 | 2017-12-29 | ||
| PCT/CN2018/118303 WO2019105437A1 (zh) | 2017-12-01 | 2018-11-29 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023160064A Division JP7702159B2 (ja) | 2017-12-01 | 2023-09-25 | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021503930A JP2021503930A (ja) | 2021-02-15 |
| JP2021503930A5 true JP2021503930A5 (cg-RX-API-DMAC7.html) | 2022-01-06 |
| JP7360716B2 JP7360716B2 (ja) | 2023-10-13 |
Family
ID=66664716
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529419A Active JP7360716B2 (ja) | 2017-12-01 | 2018-11-29 | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| JP2023160064A Active JP7702159B2 (ja) | 2017-12-01 | 2023-09-25 | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023160064A Active JP7702159B2 (ja) | 2017-12-01 | 2023-09-25 | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12083142B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4455285A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7360716B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20250107294A (cg-RX-API-DMAC7.html) |
| CN (2) | CN118236391A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018377716B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3083970A1 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20250192T1 (cg-RX-API-DMAC7.html) |
| TW (2) | TWI891096B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019105437A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202003137B (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110944675B9 (zh) | 2017-12-01 | 2024-08-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7360716B2 (ja) | 2017-12-01 | 2023-10-13 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| CN118291456A (zh) | 2017-12-01 | 2024-07-05 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105414A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| HRP20250277T1 (hr) | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| CN110959011B (zh) | 2017-12-29 | 2023-03-28 | 苏州瑞博生物技术股份有限公司 | 缀合物及其制备方法和用途 |
| WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| JP7376952B2 (ja) | 2018-09-30 | 2023-11-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | siRNA複合体及びその調製方法と使用 |
| JP7507495B2 (ja) | 2018-12-28 | 2024-06-28 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CN113227376B (zh) | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| JP7610848B2 (ja) | 2019-05-22 | 2025-01-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| CN113286888B (zh) * | 2019-05-22 | 2023-12-22 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113795582B (zh) | 2019-05-24 | 2024-05-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113795280B (zh) * | 2019-05-24 | 2024-04-05 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| AU2021244786A1 (en) | 2020-03-25 | 2022-11-03 | Risen (Suzhou) Pharma Tech Co., Ltd. | Stable heavy isotopes in amide functional groups and uses thereof |
| KR20230022892A (ko) * | 2020-06-11 | 2023-02-16 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 이중-가닥 sirna 유도체의 접합체 |
| CN114685277A (zh) * | 2020-12-31 | 2022-07-01 | 苏州瑞博生物技术股份有限公司 | 化合物及羟基丙酸盐类化合物的纯化方法 |
| EP4372086A4 (en) * | 2021-07-16 | 2026-06-17 | Suzhou Ribo Life Science Co Ltd | DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE CONTAINING A DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION PROCESSES AND USES |
| CN115819484B (zh) * | 2021-07-23 | 2026-06-02 | 苏州瑞博生物技术股份有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
| CN115677770A (zh) * | 2021-07-23 | 2023-02-03 | 北京瑞博开拓医药科技有限公司 | 修饰核苷单体、包含修饰核苷酸的siRNA、药物组合物和缀合物 |
| WO2023116607A1 (zh) | 2021-12-21 | 2023-06-29 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2023116764A1 (zh) * | 2021-12-23 | 2023-06-29 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及其用途 |
| US20250325675A1 (en) * | 2022-04-14 | 2025-10-23 | Suzhou Ribo Life Science Co., Ltd. | Aptamer, conjugate, composition, method for preparing same, and use thereof |
| KR20250043473A (ko) * | 2022-07-27 | 2025-03-28 | 이-테라퓨틱스 피엘씨 | 핵산 화합물 |
| CN120752340A (zh) * | 2023-02-24 | 2025-10-03 | 重庆药友制药有限责任公司 | 包合R和E的双链siRNA类似物及其缀合物 |
| WO2025242164A1 (zh) * | 2024-05-23 | 2025-11-27 | 正大天晴药业集团股份有限公司 | siRNA剂与逆转录酶抑制剂的联合及其治疗乙肝的用途 |
Family Cites Families (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030206887A1 (en) | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| CA2350882C (en) | 1998-11-12 | 2011-02-22 | Life Technologies Corporation | Transfection reagents |
| EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| CN1257284C (zh) | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | 一种体外阻断乙肝病毒表达的方法 |
| EP2669377A3 (en) | 2003-04-17 | 2015-10-14 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
| CA2566286A1 (en) | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
| US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
| EP2990410A1 (en) | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| KR20100060018A (ko) | 2005-03-09 | 2010-06-04 | 재단법인 목암생명공학연구소 | 작은 간섭 rna 및 이를 포함하는 b형 간염 바이러스 치료용 약학 조성물 |
| US7605251B2 (en) | 2006-05-11 | 2009-10-20 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the PCSK9 gene |
| CA2658183A1 (en) | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina) |
| WO2008109369A2 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tnf gene expression and uses thereof |
| EP2229186A2 (en) | 2007-12-04 | 2010-09-22 | Alnylam Pharmaceuticals Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| AU2014208251B2 (en) | 2007-12-04 | 2016-07-14 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| CA2713379A1 (en) | 2008-01-31 | 2009-11-05 | Alnylam Pharmaceuticals, Inc. | Optimized methods for delivery of dsrna targeting the pcsk9 gene |
| EP3643782A1 (en) | 2008-02-11 | 2020-04-29 | Phio Pharmaceuticals Corp. | Modified rnai polynucleotides and uses thereof |
| CN101603042B (zh) | 2008-06-13 | 2013-05-01 | 厦门大学 | 可用于乙型肝炎病毒感染治疗的rna干扰靶点 |
| WO2010012244A1 (zh) | 2008-08-01 | 2010-02-04 | 苏州瑞博生物技术有限公司 | 乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用 |
| CA2740785C (en) | 2008-10-15 | 2017-06-20 | Isis Pharmaceuticals, Inc. | Modulation of factor 11 expression |
| JP2012511915A (ja) | 2008-12-17 | 2012-05-31 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション | 鳥類の性別の調節方法 |
| EP2405921A4 (en) | 2009-01-26 | 2013-05-22 | Protiva Biotherapeutics Inc | COMPOSITIONS AND METHODS FOR VAPORING APOLIPOPROTIEN C-III EXPRESSION |
| US8975389B2 (en) | 2009-03-02 | 2015-03-10 | Alnylam Pharmaceuticals, Inc. | Nucleic acid chemical modifications |
| RU2011146158A (ru) | 2009-04-15 | 2013-05-27 | АйЭсАйЭс ФАРМАСЬЮТИКАЛЗ, ИНК. | Модуляция воспалительных реакций фактором хi |
| KR101224828B1 (ko) * | 2009-05-14 | 2013-01-22 | (주)바이오니아 | siRNA 접합체 및 그 제조방법 |
| US9051567B2 (en) | 2009-06-15 | 2015-06-09 | Tekmira Pharmaceuticals Corporation | Methods for increasing efficacy of lipid formulated siRNA |
| NZ597504A (en) | 2009-06-15 | 2013-10-25 | Alnylam Pharmaceuticals Inc | Lipid formulated dsrna targeting the pcsk9 gene |
| JP2014501097A (ja) | 2009-07-06 | 2014-01-20 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 生物由来物質の産生を高めるための組成物及び方法 |
| CA2677068A1 (en) | 2009-09-01 | 2011-03-01 | Mdrna, Inc. | Nucleic acid compounds for inhibiting gene expression and uses thereof |
| WO2011028938A1 (en) | 2009-09-02 | 2011-03-10 | Alnylam Pharmaceuticals, Inc. | Methods for lowering serum cholestrol in a subject using inhibition of pcsk9 |
| US9187746B2 (en) | 2009-09-22 | 2015-11-17 | Alnylam Pharmaceuticals, Inc. | Dual targeting siRNA agents |
| WO2011085271A2 (en) | 2010-01-08 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| CN102140459B (zh) * | 2010-01-29 | 2013-04-03 | 苏州瑞博生物技术有限公司 | 一种小干扰核酸和药物组合物及其制药应用 |
| CN102140458B (zh) | 2010-01-29 | 2013-05-22 | 苏州瑞博生物技术有限公司 | 小干扰核酸和药物组合物及其制药应用 |
| CN102140460B (zh) * | 2010-01-29 | 2012-12-12 | 苏州瑞博生物技术有限公司 | 小干扰核酸和药物组合物及其制药应用 |
| CN102140461B (zh) | 2010-01-29 | 2012-12-05 | 苏州瑞博生物技术有限公司 | 小干扰核酸和药物组合物及其制药应用 |
| PH12012501596A1 (en) | 2010-02-24 | 2017-02-03 | Arrowhead Res Corporation | Compositions for targeted delivery of sirna |
| RU2012147589A (ru) | 2010-04-09 | 2014-05-20 | Мерк Шарп Энд Домэ Корп. | Новые отдельные химические структурные единицы и способы доставки олигонуклеотидов |
| WO2011139702A2 (en) | 2010-04-28 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Modified nucleosides and oligomeric compounds prepared therefrom |
| WO2011154331A1 (en) | 2010-06-10 | 2011-12-15 | F. Hoffmann-La Roche Ag | Polymers for delivery of nucleic acids |
| CN102344477B (zh) | 2010-07-27 | 2015-04-08 | 苏州瑞博生物技术有限公司 | 一种核苷酸和/或寡核苷酸及其制备方法 |
| RU2745848C2 (ru) | 2010-08-17 | 2021-04-01 | Сирна Терапьютикс, Инк. | ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) |
| US9290760B2 (en) | 2010-09-15 | 2016-03-22 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
| WO2012058693A2 (en) | 2010-10-29 | 2012-05-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of pcsk9 genes |
| ES2702428T3 (es) | 2010-11-15 | 2019-02-28 | Life Technologies Corp | Reactivos de transfección que contienen amina y métodos para prepararlos y usarlos |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| RU2582235C2 (ru) | 2010-12-29 | 2016-04-20 | Ф.Хоффманн-Ля Рош Аг | Низкомолекулярные конъюгаты для внутриклеточной доставки нуклеиновых кислот |
| KR102011156B1 (ko) | 2011-01-06 | 2019-08-16 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
| KR102104401B1 (ko) | 2011-03-29 | 2020-04-27 | 알닐람 파마슈티칼스 인코포레이티드 | Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법 |
| CN102719434A (zh) | 2011-03-31 | 2012-10-10 | 百奥迈科生物技术有限公司 | 抑制rna干扰脱靶效应的特异性修饰 |
| DK2694108T3 (en) | 2011-04-08 | 2018-08-20 | Univ Leicester | METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION |
| CN102727907B (zh) | 2011-04-13 | 2015-03-11 | 苏州瑞博生物技术有限公司 | 一种小干扰rna药物的给药系统和制剂 |
| SG194671A1 (en) | 2011-04-27 | 2013-12-30 | Isis Pharmaceuticals Inc | Modulation of apolipoprotein ciii (apociii) expression |
| CA2839573A1 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
| PT2726613T (pt) | 2011-06-30 | 2018-10-26 | Arrowhead Pharmaceuticals Inc | Composições e métodos para inibição da expressão de genes do vírus da hepatite b |
| CN103073726B (zh) | 2011-10-26 | 2015-09-23 | 苏州瑞博生物技术有限公司 | 嵌段共聚物与液体组合物和核酸制剂及其制备方法和应用 |
| US9512073B2 (en) | 2011-10-27 | 2016-12-06 | Massachusetts Institute Of Technology | Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof |
| CA2853609A1 (en) * | 2011-10-28 | 2013-05-02 | University Of The Witwatersrand, Johannesburg | Inhibition of viral gene expression |
| AU2012327227A1 (en) | 2011-11-07 | 2013-05-23 | Isis Pharmaceuticals, Inc. | Administration of Factor XI antisense oligonucleotides |
| AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| EP4253395A3 (en) | 2012-08-06 | 2023-11-29 | Alnylam Pharmaceuticals, Inc. | Processes for the preparation of carbohydrate conjugated rna agents |
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| BR112015013105B1 (pt) | 2012-12-05 | 2022-02-08 | Alnylam Pharmaceuticals, Inc | Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro |
| CA2893801A1 (en) | 2013-01-30 | 2014-08-07 | F. Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
| PT2970974T (pt) | 2013-03-14 | 2017-11-29 | Alnylam Pharmaceuticals Inc | Composições de irna de componente do complemento c5 e métodos para a sua utilização |
| PL2992098T3 (pl) | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| WO2014182661A2 (en) | 2013-05-06 | 2014-11-13 | Alnylam Pharmaceuticals, Inc | Dosages and methods for delivering lipid formulated nucleic acid molecules |
| CN104107437B (zh) | 2013-06-09 | 2015-08-26 | 厦门成坤生物技术有限公司 | 一种用于治疗乙型病毒性肝炎的rna干扰组合物及其制备方法 |
| WO2014205451A2 (en) | 2013-06-21 | 2014-12-24 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| JP2016528890A (ja) | 2013-07-09 | 2016-09-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | CRISPR/Cas系を用いるゲノム編集の治療用の使用 |
| WO2015006740A2 (en) * | 2013-07-11 | 2015-01-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
| EP3027222A1 (en) | 2013-07-31 | 2016-06-08 | QBI Enterprises Ltd. | Sphingolipid-polyalkylamine-oligonucleotide compounds |
| US9670492B2 (en) | 2013-08-28 | 2017-06-06 | Ionis Pharmaceuticals, Inc. | Modulation of prekallikrein (PKK) expression |
| WO2015051366A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Novel formats for organic compounds for use in rna interference |
| ES2738289T3 (es) | 2013-11-06 | 2020-01-21 | Hospital Clinic Barcelona | Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión |
| PL3087183T3 (pl) | 2013-12-24 | 2021-01-11 | Ionis Pharmaceuticals, Inc. | Modulacja ekspresji białka angiopoetynopodobnego 3 |
| ES3065185T3 (en) | 2014-01-21 | 2026-05-04 | Takeda Pharmaceuticals Co | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
| US10358643B2 (en) | 2014-01-30 | 2019-07-23 | Hoffmann-La Roche, Inc. | Poly oligomer compound with biocleavable conjugates |
| JP6752151B2 (ja) | 2014-03-25 | 2020-09-09 | アークトゥラス・セラピューティクス・インコーポレイテッドArcturus Therapeutics,Inc. | 遺伝子サイレンシングにおいて低下したoff−target効果を有するunaオリゴマー |
| HUE052709T2 (hu) | 2014-05-01 | 2021-05-28 | Ionis Pharmaceuticals Inc | Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására |
| WO2015168589A2 (en) | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
| CN107109405A (zh) | 2014-06-06 | 2017-08-29 | 索尔斯蒂斯生物有限公司 | 具有生物可逆性和非生物可逆性基团的多核苷酸构建体 |
| EP3151839A4 (en) | 2014-06-06 | 2018-02-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds |
| EP3736334A1 (en) | 2014-07-16 | 2020-11-11 | Arrowhead Pharmaceuticals, Inc. | Rnai compositions to treat apoc3-related diseases |
| IL316808A (en) | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| CN104232644B (zh) | 2014-09-03 | 2016-10-12 | 浙江大学 | 一种特异抑制XOR基因表达的siRNA及其应用 |
| WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| TWI769565B (zh) | 2014-11-10 | 2022-07-01 | 美商阿尼拉製藥公司 | B型肝炎病毒(HBV)iRNA組成物及其用途方法 |
| WO2016081444A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| WO2016099982A2 (en) | 2014-12-15 | 2016-06-23 | Emory University | Phosphoramidates for the treatment of hepatitis b virus |
| US10036017B2 (en) | 2015-02-17 | 2018-07-31 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA |
| MX2017011422A (es) | 2015-03-17 | 2017-11-10 | Arrowhead Pharmaceuticals Inc | Composiciones y metodos para inhibir la expresion del gen del factor xii. |
| CA2979998A1 (en) | 2015-03-20 | 2016-09-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for treating hypertriglyceridemia |
| BR112017021053A2 (en) | 2015-04-13 | 2018-08-14 | Alnylam Pharmaceuticals, Inc. | angiopoietin type 3 (angpt13) irna compositions and methods of use thereof |
| CA2984636A1 (en) | 2015-05-06 | 2016-11-10 | Alnylam Pharmaceuticals, Inc. | Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof |
| CN104922141B (zh) | 2015-05-28 | 2016-05-25 | 厦门成坤生物技术有限公司 | 一种用于治疗乙型病毒性肝炎的siRNA组合物 |
| EP3307316A1 (en) | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| EP3315608B1 (en) * | 2015-06-26 | 2020-09-16 | Suzhou Ribo Life Science Co., Ltd. | Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof |
| JP6924744B2 (ja) | 2015-07-17 | 2021-08-25 | アークトゥラス・セラピューティクス・インコーポレイテッドArcturus Therapeutics,Inc. | B型肝炎ウイルスに対する組成物および薬剤ならびにその使用 |
| WO2017019660A1 (en) | 2015-07-27 | 2017-02-02 | Alnylam Pharmaceuticals, Inc. | Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof |
| CN108350455A (zh) | 2015-07-29 | 2018-07-31 | 阿布特斯生物制药公司 | 用于使b型肝炎病毒基因表达沉默的组合物和方法 |
| CN115957337A (zh) | 2015-08-07 | 2023-04-14 | 箭头药业股份有限公司 | 乙型肝炎病毒感染的RNAi疗法 |
| EP3340994A1 (en) | 2015-08-25 | 2018-07-04 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder |
| WO2017055627A1 (en) | 2015-10-02 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Apoc3 mutations for the diagnosis and therapy of hereditary renal amyloidosis disease |
| EP3387129A1 (en) | 2015-12-10 | 2018-10-17 | Alnylam Pharmaceuticals, Inc. | STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| US10883107B2 (en) | 2016-01-08 | 2021-01-05 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereof |
| KR20180103166A (ko) | 2016-01-29 | 2018-09-18 | 교와 핫꼬 기린 가부시키가이샤 | 핵산 복합체 |
| MA45295A (fr) | 2016-04-19 | 2019-02-27 | Alnylam Pharmaceuticals Inc | Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser |
| MD3448426T2 (ro) | 2016-04-28 | 2025-09-30 | Regeneron Pharma | Metode de tratament al pacienților cu hipercolesterolemie familială |
| JOP20190015A1 (ar) | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| WO2018035380A1 (en) | 2016-08-17 | 2018-02-22 | Solstice Biologics, Ltd. | Polynucleotide constructs |
| JOP20170056B1 (ar) | 2016-09-02 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة |
| HRP20240930T1 (hr) | 2016-10-18 | 2024-10-11 | Novartis Ag | Postupci za prevenciju kardiovaskularnih događaja smanjenjem proteina proproteinske konvertaze suptilizin/keksin tipa 9 (pcsk9) |
| CN113652431A (zh) | 2016-12-21 | 2021-11-16 | 苏州瑞博生物技术股份有限公司 | 一种小干扰核酸和药物组合物及其用途 |
| CN108239644B (zh) | 2016-12-23 | 2021-05-28 | 苏州瑞博生物技术股份有限公司 | 一种小干扰核酸和药物组合物及其用途 |
| CN108265052B (zh) | 2016-12-30 | 2021-05-28 | 苏州瑞博生物技术股份有限公司 | 一种小干扰核酸和药物组合物及其用途 |
| CN110234326B (zh) | 2017-01-30 | 2024-11-12 | 箭头药业股份有限公司 | 用于抑制因子xii基因表达的组合物和方法 |
| CA3059426A1 (en) | 2017-04-11 | 2018-10-18 | Arbutus Biopharma Corporation | Targeted compositions |
| CN108929870B (zh) | 2017-05-19 | 2020-01-24 | 百奥迈科生物技术有限公司 | 抑制HBV的siRNA分子及其应用 |
| CN111164091B (zh) | 2017-06-02 | 2025-01-07 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
| CN111279484B (zh) | 2017-11-09 | 2024-09-17 | 索尼半导体解决方案公司 | 固态成像装置和电子设备 |
| JP7360716B2 (ja) | 2017-12-01 | 2023-10-13 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| HRP20250277T1 (hr) | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| WO2019105403A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN110944675B9 (zh) | 2017-12-01 | 2024-08-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105414A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN118291456A (zh) | 2017-12-01 | 2024-07-05 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN111050807B (zh) | 2017-12-01 | 2024-05-28 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN110959011B (zh) * | 2017-12-29 | 2023-03-28 | 苏州瑞博生物技术股份有限公司 | 缀合物及其制备方法和用途 |
| WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| JP7376952B2 (ja) | 2018-09-30 | 2023-11-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | siRNA複合体及びその調製方法と使用 |
| EP3873486A4 (en) | 2018-11-02 | 2022-10-19 | Arbutus Biopharma Corporation | Bivalent targeted conjugates |
| CN112423795B (zh) | 2018-12-28 | 2026-06-26 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN113330117B (zh) | 2019-01-18 | 2024-05-28 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN111979237A (zh) | 2019-05-22 | 2020-11-24 | 苏州瑞博生物技术股份有限公司 | 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途 |
| CN111973618B (zh) | 2019-05-23 | 2024-02-02 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与siRNA缀合物及制备方法和用途 |
| CN111973617A (zh) | 2019-05-23 | 2020-11-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN111973619B (zh) | 2019-05-23 | 2024-01-30 | 苏州瑞博生物技术股份有限公司 | 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途 |
-
2018
- 2018-11-29 JP JP2020529419A patent/JP7360716B2/ja active Active
- 2018-11-29 US US16/765,799 patent/US12083142B2/en active Active
- 2018-11-29 KR KR1020257022150A patent/KR20250107294A/ko active Pending
- 2018-11-29 EP EP24197689.3A patent/EP4455285A3/en active Pending
- 2018-11-29 WO PCT/CN2018/118303 patent/WO2019105437A1/zh not_active Ceased
- 2018-11-29 CN CN202410305806.5A patent/CN118236391A/zh active Pending
- 2018-11-29 CN CN201880049564.0A patent/CN110945132B/zh active Active
- 2018-11-29 HR HRP20250192TT patent/HRP20250192T1/hr unknown
- 2018-11-29 CA CA3083970A patent/CA3083970A1/en active Pending
- 2018-11-29 KR KR1020207015745A patent/KR102834361B1/ko active Active
- 2018-11-29 AU AU2018377716A patent/AU2018377716B2/en active Active
- 2018-11-29 EP EP18883153.1A patent/EP3719125B1/en active Active
- 2018-11-30 TW TW112140948A patent/TWI891096B/zh active
- 2018-11-30 TW TW107142922A patent/TWI823879B/zh active
-
2020
- 2020-05-27 ZA ZA2020/03137A patent/ZA202003137B/en unknown
-
2023
- 2023-09-25 JP JP2023160064A patent/JP7702159B2/ja active Active
-
2024
- 2024-07-22 US US18/780,176 patent/US20240382514A1/en active Pending
-
2025
- 2025-01-31 AU AU2025200653A patent/AU2025200653A1/en active Pending